Tyra biosciences, inc. announces $200 million private placement financing

Carlsbad, calif. , feb. 2, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the pipe) for gross proceeds of approximately $200 million.
TYRA Ratings Summary
TYRA Quant Ranking